World Health Organization. Hepatitis C: fact sheet. Available at http://www.who.int/mediacentre/factsheets/fs164/en/. Updated: October 2017; Accessed: January 23, 2018.
Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000 Mar 11. 355(9207):887-91. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013 May 10. 62 (18):362-5. [QxMD MEDLINE Link]. [Full Text].
Kim A. Hepatitis C virus. Ann Intern Med. 2016 Sep 6. 165 (5):ITC33-ITC48. [QxMD MEDLINE Link].
Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999 Aug 19. 341(8):556-62. [QxMD MEDLINE Link].
Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012 Feb 21. 156(4):271-8. [QxMD MEDLINE Link].
American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA). Testing, evaluate, monitor. Overview of cost, reimbursement, and cost-effectiveness considerations for hepatitis C treatment regimens. Available at https://www.hcvguidelines.org/evaluate/cost. Updated: September 21, 2017; Accessed: January 25, 2018.
Toich L. Will hepatitis C virus medication costs drop in the years ahead?. Pharmacy Times. Available at https://www.pharmacytimes.com/resource-centers/hepatitisc/will-hepatitis-c-virus-medicaton-costs-drop-in-the-years-ahead. February 8, 2017; Accessed: January 25, 2018.
[Guideline] American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Updated: May 24, 2018. Available at https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_May_24_2018b.pdf. Accessed: January 9, 2019.
Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30. 321(22):1501-6. [QxMD MEDLINE Link].
Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006 Feb. 8(1):53-9. [QxMD MEDLINE Link].
Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol. 2001 Feb. 44(2):159-82. [QxMD MEDLINE Link].
Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5. 345 (1):41-52. [QxMD MEDLINE Link].
Ghany MG, Liang TJ. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013 Aug 15. 369 (7):679-80. [QxMD MEDLINE Link].
Mahmoudvand S, Shokri S, Taherkhani R, Farshadpour F. Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma. World J Gastroenterol. 2019 Jan 7. 25 (1):42-58. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention. Viral hepatitis. Hepatitis C FAQs for health professionals. Available at https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Updated: January 27, 2017; Accessed: January 10, 2018.
Rischitelli G, Harris J, McCauley L, Gershon R, Guidotti T. The risk of acquiring hepatitis B or C among public safety workers: a systematic review. Am J Prev Med. 2001 May. 20(4):299-306. [QxMD MEDLINE Link].
Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013 Mar. 57 (3):881-9. [QxMD MEDLINE Link].
Wilkin T. Clinical practice. Primary care for men who have sex with men. N Engl J Med. 2015 Aug 27. 373 (9):854-62. [QxMD MEDLINE Link].
Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014 Sep 15. 59 (6):765-73. [QxMD MEDLINE Link].
Gartner LM, Morton J, Lawrence RA, Naylor AJ, O'Hare D, Schanler RJ, et al. Breastfeeding and the use of human milk. Pediatrics. 2005 Feb. 115 (2):496-506. [QxMD MEDLINE Link].
Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018 Feb. 108 (2):175-81. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention. Viral hepatitis: surveillance for viral hepatitis – United States, 2015. Available at https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm. Updated: June 19, 2017; Accessed: January 23, 2018.
El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003 Nov 18. 139(10):817-23. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention. Viral hepatitis: statistics and surveillance. Available at https://www.cdc.gov/hepatitis/statistics/index.htm. Updated: May 11, 2017; Accessed: January 23, 2018.
Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002 Nov. 36 (5 suppl 1):S30-4. [QxMD MEDLINE Link].
Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997 Nov 14. 72(46):341-4. [QxMD MEDLINE Link].
Al-Raddadi RM, Dashash NA, Alghamdi HA, Al-Raddadi ZM, Alzahrani HS, Alsahafi AJ, et al. Hepatitis C virus infection in Jeddah city, Saudi Arabia: seroprevalence and knowledge. J Med Virol. 2018 Mar. 90 (3):526-31. [QxMD MEDLINE Link].
Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000. 20 (1):1-16. [QxMD MEDLINE Link].
Emmanuel B, Shardell MD, Tracy L, Kottilil S, El-Kamary SS. Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III. J Viral Hepat. 2017 May. 24 (5):380-8. [QxMD MEDLINE Link]. [Full Text].
Nakashima K, Ikematsu H, Hayashi J, Kishihara Y, Mutsutake A, Kashiwagi S. Intrafamilial transmission of hepatitis-C virus among the population of an endemic area of Japan. JAMA. 1995 Nov 8. 274(18):1459-61. [QxMD MEDLINE Link].
Osella AR, Misciagna G, Leone A, Di Leo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of Southern Italy. J Hepatol. 1997 Jul. 27(1):30-5. [QxMD MEDLINE Link].
Kiyosawa K, Tanaka E, Sodeyama T, et al. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group. Gastroenterology. 1994 Jun. 106(6):1596-602. [QxMD MEDLINE Link].
[Guideline] American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015 Sep. 62 (3):932-54. [QxMD MEDLINE Link]. [Full Text].
Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008 May. 103 (5):1283-97; quiz 1298. [QxMD MEDLINE Link].
Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998 Dec. 28(6):1687-95. [QxMD MEDLINE Link].
Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999 Apr. 29(4):1311-6. [QxMD MEDLINE Link].
Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997 Jul. 27(1):201-5. [QxMD MEDLINE Link].
Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology. 1998 Aug. 28(2):562-7. [QxMD MEDLINE Link].
Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut. 1999 Jun. 44(6):874-80. [QxMD MEDLINE Link]. [Full Text].
Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999 Apr. 29(4):1215-9. [QxMD MEDLINE Link].
McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 2014 Feb 1. 174(2):204-12. [QxMD MEDLINE Link].
Tucker ME. Hepatitis C viral suppression reduces liver morbidity, death. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/814456. 2013 Nov 15; Accessed: November 18, 2013.
Everson GT, Weinberg H. Living With Hepatitis C: A Survivor's Guide. 3rd ed. Long Island City, New York: Hatherleigh Health; 2002.
Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl. 2003 Nov. 9 (11):S48-51. [QxMD MEDLINE Link].
Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999 Oct. 42(10):2204-12. [QxMD MEDLINE Link].
Cacoub P, Renou C, Rosenthal E, et al. The GERMIVIC. Groupe. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine (Baltimore). 2000 Jan. 79(1):47-56. [QxMD MEDLINE Link].
Dervis E, Serez K. The prevalence of dermatologic manifestations related to chronic hepatitis C virus infection in a study from a single center in Turkey. Acta Dermatovenerol Alp Panonica Adriat. 2005 Sep. 14(3):93-8. [QxMD MEDLINE Link].
Maticic M. Lichen planus in hepatitis C virus infection: an early marker that may save lives. Acta Dermatovenerol Alp Panonica Adriat. 2007 Mar. 16(1):3-6. [QxMD MEDLINE Link].
[Guideline] World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva, Switzerland: World Health Organization. July 2018. Available at http://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf. Accessed: January 9, 2019.
Garcia J. Hepatitis C point-of-care tests are highly accurate. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/772679. 2012 Oct 15; Accessed: November 14, 2012.
Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med. 2012 Oct 16. 157(8):558-66. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012 Aug 17. 61:1-32. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Garcia J. Hepatitis C: USPSTF recommends all baby boomers be screened. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/806836. Jun 24 2013; Accessed: Jun 26 2013.
[Guideline] Moyer VA, U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013 Sep 3. 159(5):349-57. [QxMD MEDLINE Link]. [Full Text].
Ngo-Metzger Q, Ward JW, Valdiserri RO. Expanded hepatitis C virus screening recommendations promote opportunities for care and cure. Ann Intern Med. 2013 Sep 3. 159(5):364-5. [QxMD MEDLINE Link]. [Full Text].
Lowry F. Baby boomer Hep C screening practical in emergency department. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/822310. 2014 Mar 12; Accessed: April 1, 2014.
Galbraith JW, Morgan J, Rodgers J, et al. High yield and feasibility of baby boomer birth cohort HCV screening in two urban, academic emergency departments [abstract 59]. Presented at: International Conference on Viral Hepatitis (ICVH); March 17-18, 2014; New York, NY. [Full Text].
Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012 Jul. 55 suppl 1:S43-8. [QxMD MEDLINE Link].
Occupational Health & Safety [online]. FDA approves rapid test for antibodies to hepatitis C virus. June 28, 2010. Available at https://ohsonline.com/articles/2010/06/28/fda-approves-rapid-test-for-antibodies-to-hepatitis-c-virus.aspx?admgarea=magazine.
US Food and Drug Administration (FDA). Vaccines, blood & biologics. Complete list of donor screening assays for infectious agents and HIV diagnostic assays. Available at https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm080466.htm#HCV_NucleicAcid_Assays. Updated: January 19, 2018; Accessed: January 25, 2018.
Hologic, Inc. Aptima HCV Quant Dx Assay (US-IVD). Available at https://www.hologic.com/hologic-products/diagnostic-solutions/aptima-virology. Accessed: January 26, 2018.
Crane M. FDA approves first genotyping test for patients with HCV. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/806646. 2013 Jun 20; Accessed: June 23, 2013.
HIV.gov. FDA approves first genotyping test for patients with hepatitis C virus. June 28, 2013. Available at https://www.hiv.gov/blog/fda-approves-first-genotyping-test-for-patients-with-hepatitis-c-virus.
Amjad M, Moudgal V, Faisal M. Laboratory methods for diagnosis and management of hepatitis c virus infection. Lab Med. 7 Oct 2013. 44 (4):292-9.
Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2010 Oct 1. 51(7):788-95. [QxMD MEDLINE Link].
Della Rossa A, Tavoni A, Baldini C, Bombardieri S. Mixed cryoglobulinemia and hepatitis C virus association: ten years later. Isr Med Assoc J. 2001 Jun. 3(6):430-4. [QxMD MEDLINE Link].
Yang DH, Ho LJ, Lai JH. Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World J Gastroenterol. 2014 Mar 21. 20 (11):2962-70. [QxMD MEDLINE Link]. [Full Text].
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996 Aug. 24 (2):289-93. [QxMD MEDLINE Link].
Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995 Dec. 19 (12):1409-17. [QxMD MEDLINE Link].
Renzulli M, Buonfiglioli F, Conti F, et al. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur Radiol. 2018 Feb. 28 (2):506-13. [QxMD MEDLINE Link].
US Food and Drug Administration. 510(k) Premarket notification: Hepatiq. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K142891. Accessed: January 11, 2015.
Business Wire. Hepatiq receives FDA clearance. Hepatiq.com. Available at http://www.hepatiq.com/fdaclearshepatiq.html. 2014 Dec 19; Accessed: January 11, 2015.
HALT-C (Hepatitis C Antiviral Long-term Treatment against Cirrhosis) trial website. National Institute of Diabetes and Digestive and Kidney Diseases. Available at http://archives.niddk.nih.gov/haltctrial/displaypage.aspx?pagename=haltctrial/index.htm. Accessed: January 11, 2015.
Pickhardt PJ, Graffy PM, Said A, et al. Multiparametric CT for noninvasive staging of hepatitis C virus-related liver fibrosis: correlation with the histopathologic fibrosis score. AJR Am J Roentgenol. 2019 Jan 15. 1-7. [QxMD MEDLINE Link].
Jezequel C, Bardou-Jacquet E, Desille Y, et al. Survival of patients infected by chronic hepatitis C and F0F1 fibrosis at baseline after a 15 year follow-up. Presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria.
Mettke F, Schlevogt B, Deterding K, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther. 2018 Feb. 47 (4):516-25. [QxMD MEDLINE Link].
US Food and Drug Administration. FDA approves Sovaldi for chronic hepatitis C. FDA News Release. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377888.htm. 2013 Dec 6; Accessed: December 23, 2013.
Tucker ME. FDA approves 'game changer' hepatitis C drug sofosbuvir. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/817371. 2013 Dec 6; Accessed: December 21, 2013.
Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986 Dec 18. 315(25):1575-8. [QxMD MEDLINE Link].
Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30. 321(22):1506-10. [QxMD MEDLINE Link].
Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001 Nov 15. 345(20):1452-7. [QxMD MEDLINE Link].
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19. 339(21):1485-92. [QxMD MEDLINE Link].
Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998 Oct 31. 352(9138):1426-32. [QxMD MEDLINE Link].
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22. 358(9286):958-65. [QxMD MEDLINE Link].
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26. 347(13):975-82. [QxMD MEDLINE Link].
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2. 140(5):346-55. [QxMD MEDLINE Link].
Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010 Jan. 138(1):116-22. [QxMD MEDLINE Link].
Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010 Jan. 138(1):108-15. [QxMD MEDLINE Link].
Mira JA, Rivero-Juarez A, Lopez-Cortes LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013 Jun. 56(11):1646-53. [QxMD MEDLINE Link].
Boyer JL, Chang EB, Collyar DE, et al, for the NIH Consensus Development Panel. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements. 2002 Jun 10-12. 19 (3):1-46. [QxMD MEDLINE Link].
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17. 461(7262):399-401. [QxMD MEDLINE Link].
Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004 May. 126(5):1302-11. [QxMD MEDLINE Link].
Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology. 1995 Nov-Dec. 42(6):907-12. [QxMD MEDLINE Link].
Afdhal N, Dusheiko G, Giannini E, et al. Eltrombopag therapy for HCV-related thrombocytopenia: Final results of ENABLE 1, a phase 3 multicenter study of eltrombopag as an adjunct for antiviral treatment of hepatitis C virus-related chronic liver disease associated with thrombocytopenia. Presented at: The American Association for the Study of Liver Diseases (AASLD); November 6-9, 2011; San Francisco, CA. [Full Text].
Dusheiko G, Afdhal N, Giannini EG, et al. Results of ENABLE-2, a phase 3, placebo-controlled, multicenter study of eltrombopag, peginterferon alfa-2b, and ribavirin treatment in patients with hepatitis C and thrombocytopenia. Presented at: The 47th Annual Meeting of The European Association for the Study of the Liver (EASL); April 18-22, 2012; Barcelona, Spain. [Full Text].
Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2002 May. 26(4):731-46. [QxMD MEDLINE Link].
Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study. J Hepatol. 2012 Nov. 57(5):946-52. [QxMD MEDLINE Link]. [Full Text].
Maughan A, Ogbuagu O. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol. 2018 Feb. 14 (2):219-27. [QxMD MEDLINE Link].
Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol. 2018 Mar. 44 (2):143-60. [QxMD MEDLINE Link].
Carrasco I, Arias A, Benítez-Gutierrez L, et al. Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients. J Med Virol. 2018 Mar. 90 (3):532-6. [QxMD MEDLINE Link].
A special meeting review edition: Advances in the treatment of hepatitis C virus infection from EASL 2013: the 48th annual meeting of the European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, The Netherlands. Special reporting on: Simeprevir plus peginterferon/ribavirin is associated with a high SVR12 rate in treatment-naive patients with genotype 1 hepatitis C virus infection. Addition of simeprevir to peginterferon/ribavirin is associated with faster resolution of f... Gastroenterol Hepatol (N Y). 2013 Jun. 9 (6 suppl 3):1-18. [QxMD MEDLINE Link]. [Full Text].
US Food and Drug Administration. FDA Antiviral Drugs Advisory Committee meeting. Briefing document. Simeprevir (TMC435) treatment of patients with chronic hepatitis C. NDA 205123. October 24, 2013. Available at http://natap.org/2013/HCV/20131024-AVDAC-B1-02-Janssen_Backgrounde.pdf.
Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. J Hepatol. 2015 May. 62 (5):1047-55. [QxMD MEDLINE Link].
Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014 Jan 16. 370 (3):222-32. [QxMD MEDLINE Link].
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16. 368(20):1878-87. [QxMD MEDLINE Link].
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013 May 16. 368(20):1867-77. [QxMD MEDLINE Link].
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014 May 22. 370 (21):1993-2001. [QxMD MEDLINE Link]. [Full Text].
MS Sulkowski, M Rodriguez-Torres, JP Lalezari, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Presented at: 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 1-5, 2013; Washington, DC. [Full Text].
Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014 Nov 15. 384(9956):1756-65. [QxMD MEDLINE Link].
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17. 370(16):1483-93. [QxMD MEDLINE Link]. [Full Text].
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15. 370(20):1889-98. [QxMD MEDLINE Link]. [Full Text].
Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014 May 15. 370(20):1879-88. [QxMD MEDLINE Link]. [Full Text].
Osterweil N. Ledipasvir sofosbuvir combination cuts cirrhotic Hepatitis C. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/834869. 2014 Nov 13; Accessed: November 17, 2014.
Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir/sofosbuvir fixed-dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy [abstract LB-6]. Presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7-11, 2014; Boston, MA. [Full Text].
Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014 Mar. 146 (3):736-743.e1. [QxMD MEDLINE Link].
Deterding K, Spinner CD, Schott E, et al, for the HepNet Acute HCV IV Study Group. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017 Feb. 17 (2):215-22. [QxMD MEDLINE Link].
Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015 Jul 7. 163 (1):1-13. [QxMD MEDLINE Link].
Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-Generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016 Jan 1. 62 (1):32-6. [QxMD MEDLINE Link].
Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015 Jul 7. 163 (1):1-13. [QxMD MEDLINE Link].
Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24. 370(17):1594-603. [QxMD MEDLINE Link].
Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24. 370(17):1604-14. [QxMD MEDLINE Link].
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014 Aug. 147(2):359-365.e1. [QxMD MEDLINE Link].
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May 22. 370(21):1983-92. [QxMD MEDLINE Link].
Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May 22. 370(21):1973-82. [QxMD MEDLINE Link].
Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015 Jun 20. 385 (9986):2502-9. [QxMD MEDLINE Link].
US Food and Drug Administration. FDA approves Technivie for treatment of chronic hepatitis C genotype 4. FDA News Release. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm. July 24, 2015; Accessed: July 29, 2015.
US Food and Drug Administration. FDA approves Epclusa for treatment of chronic hepatitis C virus infection [news release]. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm508915.htm. June 28, 2016; Accessed: January 29, 2018.
Greig SL. Sofosbuvir/velpatasvir: a review in chronic hepatitis C. Drugs. 2016 Oct. 76 (16):1567-78. [QxMD MEDLINE Link].
Chidi AP, Rogal S, Bryce CL, et al. Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology. 2016 Feb. 63 (2):428-36. [QxMD MEDLINE Link].
Wyles DL, Ruane PJ, Sulkowski MS, et al, for the ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015 Aug 20. 373 (8):714-25. [QxMD MEDLINE Link].
Naggie S, Cooper C, Saag M, et al, for the ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015 Aug 20. 373 (8):705-13. [QxMD MEDLINE Link].
Villa E, Grottola A, Buttafoco P, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol. 2001 Oct. 96(10):2973-7. [QxMD MEDLINE Link].
Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003 Mar. 37(3):568-76. [QxMD MEDLINE Link].
Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009 Feb. 136(2):496-504.e3. [QxMD MEDLINE Link].
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002 Apr. 122(4):889-96. [QxMD MEDLINE Link].
Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998 Sep. 28(3):805-9. [QxMD MEDLINE Link].
[Guideline] Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004 Apr. 39(4):1147-71. [QxMD MEDLINE Link].
[Guideline] Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009 Apr. 49(4):1335-74. [QxMD MEDLINE Link]. [Full Text].
Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013 Aug. 57 suppl 2:S32-8. [QxMD MEDLINE Link]. [Full Text].
Lewis R. Hepatitis C: 6 prevention strategies that work. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/808539. 2013 Jul 26; Accessed: August 4, 2013.
Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002 May. 122(5):1303-13. [QxMD MEDLINE Link].
Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004 Apr 1. 19(7):715-27. [QxMD MEDLINE Link].
El-Khayat HR, Fouad YM, Maher M, El-Amin H, Muhammed H. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. Gut. 2017 Nov. 66 (11):2008-12. [QxMD MEDLINE Link].
Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018 Feb. 47 (3):421-31. [QxMD MEDLINE Link].
Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016 May. 63 (5):1493-505. [QxMD MEDLINE Link].
Wyles DL, Ruane PJ, Sulkowski MS, et al, for the ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015 Aug 20. 373 (8):714-25. [QxMD MEDLINE Link]. [Full Text].
Nelson DR, Cooper JN, Lalezari JP, et al, for the ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr. 61 (4):1127-35. [QxMD MEDLINE Link]. [Full Text].
Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000 Jan 18. 132(2):105-11. [QxMD MEDLINE Link].
Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999 Sep 16. 341(12):866-70. [QxMD MEDLINE Link].
Obando J, Tortorelli K, Banner B, Stefancyk D, Bonkovsky HL. Iron: the major HFE gene mutation and chronic hepatitis C [abstract]. Gastroenterology. 2000. 118:A593.
Banner BF, Karamitsios N, Smith L, Bonkovsky HL. Enhanced phenotypic expression of alpha-1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C. Am J Gastroenterol. 1998 Sep. 93(9):1541-5. [QxMD MEDLINE Link].
Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000 Dec 7. 343(23):1666-72. [QxMD MEDLINE Link].
Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000 Dec 7. 343(23):1673-80. [QxMD MEDLINE Link].
Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012 Jan 19. 366(3):216-24. [QxMD MEDLINE Link].
US Food and Drug Administration. FDA approves new treatment for chronic hepatitis C genotype 3 infections. FDA News Release. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455888.htm. July 24, 2015; Accessed: July 29, 2015.
Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31. 364(13):1207-17. [QxMD MEDLINE Link]. [Full Text].
Barber J. Hepatitis C treated with oral nucleotide inhibitor. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/777097. 2013 Jan 03; Accessed: March 13, 2013.
Boggs W. Widespread morbilliform rash does not preclude telaprevir treatment for HCV. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/823703. 2014 Apr 16; Accessed: April 20, 2014.
Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004 Jul 29. 351(5):451-9. [QxMD MEDLINE Link]. [Full Text].
Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003 Dec. 18(11-12):1071-81. [QxMD MEDLINE Link].
US Food and Drug Administration. FDA approves Incivek for hepatitis C. FDA News Release. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm. 2011 May 23; Accessed: May 23, 2011.
Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013 Jan. 11(1):81-87.e4; quiz e5. [QxMD MEDLINE Link].
Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology. 2011 Sep. 141(3):881-889.e1. [QxMD MEDLINE Link].
Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013 Jan 3. 368(1):34-44. [QxMD MEDLINE Link].
Volansky R. HCV recommendations updated to include patients with limited resources. Healio.com. Available at http://www.healio.com/infectious-disease/hepatitis-c/news/online/%7B7377b5a9-e35d-4143-98c4-b86c0d552596%7D/hcv-recommendations-updated-to-include-patients-with-limited-resources. 2014 Aug 11; Accessed: August 16, 2014.
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013 May 16. 368(20):1867-77. [QxMD MEDLINE Link].
Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004 Sep 3. 18(13):F27-36. [QxMD MEDLINE Link].
Liu CH, Liang CC, Liu CJ, et al. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis. 2010 Sep 1. 51(5):541-9. [QxMD MEDLINE Link].
Lowes R. CDC urges second test to catch hepatitis C infection. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/803727. 2013 May 7; Accessed: May 8, 2013.
Lowes R. FDA OKs first combo drug (Harvoni) for hepatitis C. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/833108. October 10, 2014; Accessed: October 20, 2014.
Lowry F. Hepatitis C treatment viable in primary care. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/822130. 2014 Mar 18; Accessed: March 18, 2014.
McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009 Apr 30. 360(18):1827-38. [QxMD MEDLINE Link].
Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc. 2003 Dec. 35(8):3042-4. [QxMD MEDLINE Link].
Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 Jul. 8(7):623-9. [QxMD MEDLINE Link].
[Guideline] World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: updated version (April 2016). 2016 Apr. [QxMD MEDLINE Link]. [Full Text].
Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org., Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol. 2017 Nov. 217 (5):B2-B12. [QxMD MEDLINE Link].
Chou R, Easterbrook P, Hellard M. Methodological challenges in appraising evidence on diagnostic testing for WHO guidelines on hepatitis B and hepatitis C virus infection. BMC Infect Dis. 2017 Nov 1. 17 (suppl 1):694. [QxMD MEDLINE Link]. [Full Text].
Hellard ME, Chou R, Easterbrook P. WHO guidelines on testing for hepatitis B and C - meeting targets for testing. BMC Infect Dis. 2017 Nov 1. 17 (suppl 1):703. [QxMD MEDLINE Link]. [Full Text].
